The Evaluation of Molecular Markers From PRedittivI DNA of Clinical Outcomes in Patients With UROthelial Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

210 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The genetic characterization of urothelial tumor disease has brought to light important information about the biology of the disease. The evaluation of molecular DNA markers on tumor tissue could be an approach able to provide important information on the possible aggressiveness of the disease and the sensitivity/resistance profile to drugs commonly adopted in the advanced stage. The main objective of this study is to identify specific molecular profiles from DNA capable of predicting the clinical course of the disease and the possible sensitivity/resistance of the disease to systemic treatments

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Urine-DNA Biomarkers in Detecting Bladder Cancer

NCT03066310

Bladder Cancer Biomarker Diagnosis +1 more

COMPLETED

Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma

NCT06863870

Melanoma Neoplasms

ACTIVE_NOT_RECRUITING

Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients

NCT03079947

Diffuse Large B Cell Lymphoma Peripheral T Cell Lymphoma

UNKNOWN

Urine Methylation Markers in UTUC

NCT06805630

Upper Tract Urothelial Cancer

RECRUITING NA

ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

NCT05630131

Bladder Cancer Muscle-Invasive Bladder Carcinoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

retrospective and prospective evaluation concerning the identification of molecular profiles on DNA obtained from tumor tissue previously obtained from patients with urothelial cancer and analyzed with massive sequencing method (Next Generation Sequencing).

Analysis of data obtained from anamnestic data, clinical data, blood chemistry tests, histopathological examinations and instrumental imaging.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urothelial Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients diagnosed with locally advanced operated or metastatic urothelial cancer in follow-up or treatment

Exclusion Criteria

\- Deceased patients who have not already performed the NGS analysis from clinical practice.

For the prospective part:

Patients

* aged \> 18 years
* suffering from locally advanced or metastatic urothelial neoplasia
* with the availability of tumor tissue obtained during surgery on a primary tumor or metastasis or during a diagnostic biopsy.

Patients included in the study will also have to consciously express their willingness to participate in the study after signing the written informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No